News
Atai Life delivers results from PCN-101 study
Atai Life Sciences has announced the results from Perception Neuroscience’s intravenous-to-subcutaneous bridging study of its PCN-101 (R-ketamine) candidate
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Atai Life Sciences has announced the results from Perception Neuroscience’s intravenous-to-subcutaneous bridging study of its PCN-101 (R-ketamine) candidate